SecBot SecBot

ABCL

AbCellera Biologics Inc.
Nasdaq· Pharmaceutical Preparations· Inc. A1· CIK 0001703057 Biotech & Drug Discovery
$11.12 −0.37 (−3.22%)
Nov 16 4:00 PM ET · prev $11.49
Market cap
$3.8B
Mid cap
Consensus
Buy
89% Buy or better · 18 analysts
Median target
🔒 Subscribers only
1 year
+208.9%
from $3.60 · Nov 17
30 days
−6.8%
from $11.93
52-week range
$2.78–14.82
−25% from high · low Feb 5
Avg volume 20D
3.17M
shares / day
Short interest
29.02M
≈9.0% of shares · −6.2%
Days to cover
8.5
at average volume
Insider net
+$2.7M
4 buyers · 0 sellers · 12 mo
New fund stakes
1
Q2 2026 13F · 0 exits
Filing reports
16
analyzed by SecBot
SecBot read BULLISH 5 reports · 90 days
Balance 0 bearish · 2 bullish · 1 mixed · 2 neutral oldest → newest, height = score
Avg score ·High conf. 3/5

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBULLISH

    4 insiders bought $2.7M at an average $8.56. No open-market sales. Price is 30% above their cost.

  • InstitutionsMIXED

    Q2 2026: 15 added (1 new), 19 trimmed or exited. Largest new: Price T Rowe Associates /Md/ $12.5M.

  • AnalystsBULLISH

    16 of 18 rate it Buy or better.

  • Short sellersSTEADY

    Short interest −6.2% to 29.02M shares. 8.5 days to cover, ≈9.0% of shares.

  • TrendDOWNTREND

    10% below its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Oct 30.

Who's buying

13F· Q2 2026
1
new positions
0
exits
$12.5M
in new stakes
FundMoveSharesValue
BANK OF AMERICA CORP /DE/DOUBLED6,141,539$48.2M
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCTRIM4,317,206$33.9M
DRIEHAUS CAPITAL MANAGEMENT LLCTRIM2,864,729$22.5M
MARSHALL WACE, LLPDOUBLED1,902,191$14.9M
UBS Group AGTRIM1,870,633$14.7M
PRICE T ROWE ASSOCIATES INC /MD/NEW1,587,870$12.5M
NATIONAL BANK OF CANADA /FI/DOUBLED1,233,014$9.7M
RENAISSANCE TECHNOLOGIES LLCTRIM990,929$7.8M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

18 analysts
Buy 89% rate it Buy or better
Strong Buy3Buy13Hold2Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Nov 16, 2026🔒 Fresh data, subscribers only
MAINTAIN
MAINTAIN
Nov 11, 2026StoneX
MAINTAIN
MAINTAINBuy
Nov 10, 2026Stifel
MAINTAIN
MAINTAINBuy
Oct 12, 2026UBS
INITIATE
INITIATEBuy
Sep 29, 2026JP Morgan
INITIATE
INITIATEOverweight
Aug 11, 2026Truist Securities
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$2.7M
bought · 4 insiders
$0
sold · 0 insiders
+29.9%
vs their $8.56 cost
DateInsiderTypeValue
Nov 13, 2026🔒 Fresh data, subscribers only
Nov 13, 2026
GIFT
Nov 13, 2026🔒 Fresh data, subscribers only
Nov 13, 2026
EXERCISE
Nov 13, 2026
Booth Andrew
Chief Financial Officer
Nov 13, 2026
BUY$97.4K
Nov 13, 2026
Thermopylae Holdings Ltd.
10%+ Owner
Nov 13, 2026
GIFT125,000 sh
Nov 12, 2026
Thermopylae Holdings Ltd.
10%+ Owner
Nov 12, 2026
BUY$698.9K
Aug 24, 2026
Hayden Michael R
Director
Aug 24, 2026
BUY$570.4K
Aug 18, 2026
Montalbano John S.
Director
Aug 18, 2026
BUY$110.3K
Aug 14, 2026
Booth Andrew
Chief Financial Officer
Aug 14, 2026
BUY$383.9K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Reddit
Recent posts
All social signals and their track records

Short side

FINRA· Oct 30, 2026
29,023,512
shares short
-6.2%
vs prior settlement
8.5
days to cover
≈9.0%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 15, 2026 Clinical trial readout
🔒 Fresh data, subscribers only
Nov 13, 2026 SEC
CEO Carl Hansen filed an amended Schedule 13G/A disclosing a 19.7% beneficial ownership stake in AbCellera as of…
SC 13G/A · Impact 2/10
Nov 13, 2026 SEC
Two insiders at AbCellera, including the CFO and a 10% owner, made open-market purchases totaling $796K over the past…
CLUSTER · Impact 4/10
Nov 13, 2026 SEC
Two insiders at AbCellera, including the CFO and a 10% owner, made open-market purchases totaling $796K in the week…
CLUSTER · Impact 4/10
Nov 13, 2026 Insider
🔒 Fresh data, subscribers only
Nov 13, 2026 Insider
🔒 Fresh data, subscribers only
Nov 13, 2026 Insider
Booth Andrew bought 8,600 shares
Chief Financial Officer @ $11.33 ($97.4K)
Jun 30, 2026 Inst.
BANK OF AMERICA CORP · DOUBLED
6,141,539 shares ($48.2M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
7 drugs tracked · Drug pipeline →
Recent

SecBot reports

16 filings · 8 bullish · 2 bearish · 1 mixed · 5 neutral
All ABCL filing & press-release reports (16)